Literature DB >> 16127953

Management of gallstones.

Charles F Bellows1, David H Berger, Richard A Crass.   

Abstract

Many patients with gallstones can be managed expectantly. Generally, only persons with symptoms related to the presence of gallstones (e.g., steady, nonparoxysmal pain lasting four to six hours located in the upper abdomen) or complications (such as acute cholecystitis or gallstone pancreatitis) warrant surgical intervention. Biliary pain is alleviated by cholecystectomy in the majority of cases. Laparoscopic cholecystectomy is considered the most cost-effective management strategy in the treatment of symptomatic gallstones. Medical management strategies are mostly palliative and are not widely supported. Patients with longer-lasting biliary pain, in combination with abdominal tenderness, fever, and/or leukocytosis, require an ultrasound evaluation to help establish a diagnosis of acute cholecystitis. Once a patient is diagnosed, having cholecystectomy early in the course of the disease can significantly reduce the hospital stay.

Entities:  

Mesh:

Year:  2005        PMID: 16127953

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  3 in total

Review 1.  Epidemiology, management, and economic evaluation of screening of gallstone disease among type 2 diabetics: A systematic review.

Authors:  Lujie Chen; Yu-Ting Peng; Fu-Li Chen; Tao-Hsin Tung
Journal:  World J Clin Cases       Date:  2015-07-16       Impact factor: 1.337

2.  Clinically diagnosed cholecystitis: a case series.

Authors:  Firas Bridges; Jennifer Gibbs; Joshua Melamed; Edward Cussatti; Samantha White
Journal:  J Surg Case Rep       Date:  2018-02-28

Review 3.  The Need for Standardizing Diagnosis, Treatment and Clinical Care of Cholecystitis and Biliary Colic in Gallbladder Disease.

Authors:  Gerard Doherty; Matthew Manktelow; Brendan Skelly; Paddy Gillespie; Anthony J Bjourson; Steven Watterson
Journal:  Medicina (Kaunas)       Date:  2022-03-05       Impact factor: 2.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.